Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + pictilisib + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of paclitaxel (a taxane chemotherapy agent), pictilisib (a pan-phosphatidylinositol 3-kinase inhibitor), and trastuzumab (a humanized monoclonal antibody targeting HER2). The combination has been studied in clinical trials for patients with HER2-positive breast cancer. Paclitaxel works by stabilizing microtubules and preventing cell division, pictilisib inhibits the PI3K/AKT/mTOR pathway (which is associated with trastuzumab resistance), and trastuzumab targets the HER2 protein overexpressed in certain breast cancers. This triple combination aims to enhance antitumor activity and potentially overcome resistance mechanisms.
- Other names
- pictilisib + paclitaxel + trastuzumab
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + pictilisib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + pictilisib + trastuzumab.